Search results for " atrio"
showing 10 items of 12 documents
Per una lettura socio-economica dei contesti abitativi: L’insula I del Quartiere ellenistico-romano di Agrigento. La domus I A – I B
2021
In linea con le ultime ricerche organizzate dal Parco Archeologico Regionale Valle dei Templi di Agrigento, il cui scopo è la conoscenza dell'antica città di Akragas/Agrigentum come sistema integrato e unitario, si è dedicata nuova attenzione alle forme dell'abitare, in particolare nell'area del cosiddetto "Quartiere ellenistico-romano". Quest'area fu scavata negli anni '50 e '60 del secolo scorso, ma è con la pubblicazione di E. De Miro, avvenuta solo nel 2009, che è stato possibile conoscere i risultati delle indagini. In questo contributo ci si vuole concentrare sull'isolato I del Quartiere, contraddistinto da due grandi abitazioni (I A/B e I E/F) che dominano l'area pubblica dell'agorà.…
Interpretation of epicardial mapping by means of computer simulations: Applications to calcium, lidocaine and to BRL 34915
1992
The aim of this work was to compare experimental investigations on effects of lidocaine, calcium and, BRL 34915 on reentries to simulated data obtained by use of a model of propagation based on the Huygens' construction method already described in previous works. Calcium and lidocaine effects are investigated on anisotropic conduction conditions. In both cases, reduction in conduction velocities are observed. In lidocaine case, a refractory area is located along the longitudinal axis. In agreement with experimental electrical mapping, the simulations show that the stabilization of reentrant excitation is mainly due to the existence of this refractory area around which the reentrant circuit …
Chronic Apical and Nonapical Right Ventricular Pacing in Patients with High-Grade Atrioventricular Block: Results of the Right Pace Study
2018
Objective. The aim of the study was to compare the two approaches to chronic right ventricular pacing currently adopted in clinical practice: right ventricular apical (RVA) and non-RVA pacing. Background. Chronic RVA pacing is associated with an increased risk of atrial fibrillation, morbidity, and even mortality. Non-RVA pacing may yield more physiologic ventricular activation and provide potential long-term benefits and has recently been adopted as standard procedure at many implanting centers. Methods. The Right Pace study was a multicenter, prospective, single-blind, nonrandomized trial involving 437 patients indicated for dual-chamber pacemaker implantation with a high percentage of RV…
MANAGEMENT OF CHILDREN AFFECTED BY ATRIOVENTRICULAR NODAL RE-ENTRANT TACHICARDIA
2007
MANAGEMENT OF CHILDREN AFFECTED BY ATRIOVENTRICULAR NODAL RE-ENTRANT TACHICARDIA
First-degree atrioventricular block and pseudopacemaker syndrome
2013
A re-entry tachycardia triggered by the spontaneous interruption of an atrial tachycardia.
2015
The common atrioventricular nodal re-entry tachycardia is the most common form of paroxysmal supraventricular tachycardia. It starts frequently with a supraventricular ectopic beat that, on finding the fast pathway in refractory period, travels in the slow pathway as to appear as a prolongation of the PR interval on the ECG. In this study, we show a singular case of a common atrioventricular nodal re-entry tachycardia triggered by the spontaneous interruption of an atrial tachycardia.
New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) fo…
2017
There has been considerable progress in treating malignant melanoma over the last few years. The immune-checkpoint-inhibitors nivolumab and pembrolizumab have been approved by the Food and Drug Administration in 2014 for the therapy of metastatic melanoma. Anti-programmed cell death-1-blocking antibodies are known to cause immune-related adverse events. Physicians should be aware of common and rare side effects and pay attention to new ones. We therefore report a severe and life-threatening side effect of anti-programmed cell death-1 immunotherapy with nivolumab that has not been previously reported: the development of a third-degree atrioventricular block. After a second infusion with nivo…
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
2014
BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours and had their vital signs monitored hourly. Extended on-site monitoring was provided when required. RESULTS: Of the 906 p…